News & Updates

Show Multimedia Only

$Big survival gains in relapsed/refractory multiple myeloma seen with immunotherapy combo$

Big survival gains in relapsed/refractory multiple myeloma seen with immunotherapy combo

16 Jan 2026 by

For patients with multiple myeloma who have received up to three lines of therapy, combination treatment with the bispecific antibody teclistamab plus the monoclonal antibody daratumumab yields significant improvements in progression-free survival and overall survival, according to the phase III MajesTEC-3 trial.

Big survival gains in relapsed/refractory multiple myeloma seen with immunotherapy combo

16 Jan 2026

Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy

16 Jan 2026 by

Combination treatment with the CD20×CD3 bispecific antibody odronextamab and chemotherapy is generally safe among previously untreated diffuse large B cell lymphoma (DLBCL) patients, without new safety signals, as shown by the results from part 1 of the phase III Olympia-3 study.

Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy

16 Jan 2026

EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC

15 Jan 2026 by

In the phase III EPIK-B5 study, adding alpelisib, an α-specific PI3K inhibitor, to fulvestrant improves progression-free survival (PFS) in men and postmenopausal women with HR+, HER2− advanced breast cancer (ABC) harbouring a PIK3CA mutation who have progressed on or after treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).

EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC

15 Jan 2026

Risk-reducing bilateral mastectomy confers survival benefit in BRCA carriers

15 Jan 2026

Risk-reducing bilateral mastectomy in patients with the BRCA pathogenic variant appears to be associated with lower overall and breast-cancer specific mortality, according to a meta-analysis.

Risk-reducing bilateral mastectomy confers survival benefit in BRCA carriers

15 Jan 2026

Frontline anlotinib-containing regimen shows promise in advanced soft-tissue sarcoma

14 Jan 2026

In the treatment of patients with advanced soft-tissue sarcoma, combining anlotinib with anthracyclines and ifosfamide in the first-line setting followed by anlotinib maintenance has demonstrated promising efficacy, with acceptable toxicities, in a phase II study.

Frontline anlotinib-containing regimen shows promise in advanced soft-tissue sarcoma

14 Jan 2026

Metastasis-directed SBRT alone may be enough for patients with oligometastatic disease

13 Jan 2026 by

Metastasis-directed stereotactic body radiotherapy (SBRT) alone can delay the need for systemic therapy in some patients with oligometastatic cancer, with low risks of treatment-related adverse events, according to a meta-analysis.

Metastasis-directed SBRT alone may be enough for patients with oligometastatic disease

13 Jan 2026

Patient fatigue flags risk of toxicity from cancer treatment

10 Jan 2026 by

Patient fatigue reported before the initiation of cancer treatment appears to be associated with an increased risk of subsequent treatment-related adverse events, according to new research.

Patient fatigue flags risk of toxicity from cancer treatment

10 Jan 2026

T-DXd plus RT shows promise in management of metastatic breast cancer

09 Jan 2026

Combination treatment with trastuzumab deruxtecan (T-DXd) and radiation therapy (RT) may improve clinical outcomes, without compromising safety, in patients with HER2-positive and HER2-low metastatic breast cancer, reveals a study.

T-DXd plus RT shows promise in management of metastatic breast cancer

09 Jan 2026

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

09 Jan 2026 by

The results from the phase III ROP-ET trial demonstrate the potential of ropeginterferon alfa-2b (ropeg) for the treatment of essential thrombocythaemia (ET) across all risk levels in patients who are ineligible for standard cytoreduction.

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

09 Jan 2026

OAB symptoms may increase in breast cancer patients undergoing chemotherapy

08 Jan 2026

Symptoms of overactive bladder (OAC) tend to rise among women receiving both trastuzumab and pertuzumab for HER2-positive positive breast cancer during their treatment, reports a study.

OAB symptoms may increase in breast cancer patients undergoing chemotherapy

08 Jan 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

Big survival gains in relapsed/refractory multiple myeloma seen with immunotherapy combo

Big survival gains in relapsed/refractory multiple myeloma seen with immunotherapy combo

Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy

Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy

EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC

EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC

Risk-reducing bilateral mastectomy confers survival benefit in BRCA carriers

Risk-reducing bilateral mastectomy confers survival benefit in BRCA carriers

Frontline anlotinib-containing regimen shows promise in advanced soft-tissue sarcoma

Frontline anlotinib-containing regimen shows promise in advanced soft-tissue sarcoma

Metastasis-directed SBRT alone may be enough for patients with oligometastatic disease

Metastasis-directed SBRT alone may be enough for patients with oligometastatic disease

Patient fatigue flags risk of toxicity from cancer treatment

Patient fatigue flags risk of toxicity from cancer treatment

T-DXd plus RT shows promise in management of metastatic breast cancer

T-DXd plus RT shows promise in management of metastatic breast cancer

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

OAB symptoms may increase in breast cancer patients undergoing chemotherapy

OAB symptoms may increase in breast cancer patients undergoing chemotherapy